arGEN-X Awarded €1.5 Million IWT Grant to Accelerate Preclinical Antibody Development

arGEN-X BV has received a €1.5-million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders.

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of therapeutic human antibodies (mAbs), has received a €1.5-million grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT). This grant will be used to accelerate preclinical development of the lead programme, ARGX-109 and two further therapeutic mAb programmes. All three mAb candidates originated from arGEN-X’s proprietary SIMPLE Antibody platform and are being developed by the company to target the inflammation/oncology space.

This award is the second grant that arGEN-X has received from the IWT. In October 2009, the company received €1.3 million to develop and validate the SIMPLE Antibody platform, a pioneering approach to therapeutic human mAb generation.

In less than a year, the SIMPLE Antibody platform has demonstrated phenomenal productivity as a discovery engine, yielding therapeutic grade mAbs with highly differentiated fu